Effects of prulifloxacin on cardiac repolarization in healthy subjects: A Randomized, Crossover, Double-Blind versus Placebo, moxifloxacin-controlled study

Clinical Drug Investigation

Volumn 30, Issue 1, 2010, Pages 5-14

  Rosignoli, Maria Teresa ^a   Di Loreto, Giorgio ^a   Dionisio, Paolo ^a  

^a Università Politecnica delle Marche ACRAF Gruppo Angelini   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MOXIFLOXACIN; PLACEBO; PRULIFLOXACIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSSOVER PROCEDURE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG SAFETY; ELECTROCARDIOGRAM; FEMALE; HEADACHE; HEART REPOLARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NAUSEA; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; CROSS-OVER STUDIES; DIOXOLANES; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; MIDDLE AGED; PIPERAZINES;

EID: 72049109719     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11319400-000000000-00000     Document Type: Article

References (21)

1. Shah RR. Drug-induced prolongation of the QT interval: why the regulatory concern? Fundam Clin Pharmacol 2002; 16 (2): 119-124
2. Morganroth J. Cardiac repolarization and the safety of new drugs defined by electrocardiography. Clin Pharmacol Ther 2007; 81 (1): 108-113
3. Sager PT. Key clinical considerations for demonstrating the utility of preclinical models to predict clinical drug-induced torsades de pointes. Br J Pharmacol 2008; 154 (7): 1544-1549
4. Shah RR. Drugs, QTc interval prolongation and final ICH E14 guideline: an important milestone with challenges ahead. Drug Saf 2005; 28 (11): 1009-1028
5. Mehlhorn AJ, Brown DA. Safety concerns with fluoroquinolones. Ann Pharmacother 2007; 41: 1859-1866
6. Kang J, Wang L, Chen XL, et al. Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. Mol Pharmacol 2001; 59 (1): 122-126
7. Keam SJ, Perry CM. Prulifloxacin. Drugs 2004; 64 (19): 2221-2234
8. Cazzola M, Salvatori E, Dionisio P, et al. Prulifloxacin: a new fluoroquinolone for the treatment of acute exacerbation of chronic bronchitis. Pulm Pharmacol Ther 2006; 19 Suppl. 1: 30-37
9. Carmignani G, De Rose AF, Olivieri L, et al. Prulifloxacin versus ciprofloxacin in the treatment of adults with complicated urinary tract infections. Urol Int 2005; 74 (4): 326-331
10. Roveta S, Schito AM, Marchese A, et al. Microbiological rationale for the utilisation of prulifloxacin, a new fluoroquinolone, in the eradication of serious infections caused by Pseudomonas aeruginosa. Int J Antimicrob Agents 2005; 26 (5): 366-372
11. Tougou K, Nakamura A, Watanabe S, et al. Paraxonase has a major role in the hydrolysis of prulifloxacin (NM441), a prodrug of a new antibacterial agent. Drug Metab Dispos 1998; 26 (4): 355-359
12. Picollo R, Brion N, Gualano V, et al. Pharmacokinetics and tolerability of prulifloxacin after single oral administration. Arzneimittelforschung 2003; 53 (3): 201-205
13. Lacroix P,CrumbWJ,Durando L, et al. Prulifloxacin: in vitro (HERG current) and in vivo (conscious dog) assessment of cardiac risk. Eur J Pharmacol 2003 Sep 5; 477 (1): 69-72
14. Akita M, Shibazaki Y, Izumi M, et al. Comparative assessment of prulifloxacin, sparfloxacin, gatifloxacin and levofloxacin in the rabbit model of proarrhythmia. J Toxicol Sci 2004; 29 (1): 63-71
15. Data on file, ACRAF SpA, Rome, 2009
16. Malik M, Camm AJ. Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling. Drug Saf 2001; 24 (5): 323-351
17. Committee for Medicinal Products for Human Use (ICH Topic E14). Note for guidance on the clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. CHMP/ICH/2/04 London, 25 May 2005
18. Committee for Medicinal Products for Human Use (ICH Topic E14). The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs: questions and answers. EMEA/CHMP/ICH/310133/ 2008 June 2008
19. Tsikouris JP, Peeters MJ, Cox CD, et al. Effects of three fluoroquinolones on QT analysis after standard treatment courses. Ann Noninvasive Electrocardiol 2006; 11 (1): 52-56
20. Padrini R, Gusella M, Al Bunni M, et al. Tolerance to the repolarization effects of rac-sotalol during long-term treatment. Br J Clin Pharmacol 1997; 44 (5): 463-470
21. Kubitza D, Mueck W, Becka M. Randomized, doubleblind, crossover study to investigate the effect of rivaroxaban on QT-interval prolongation. Drug Saf 2008; 31 (1): 67-77